Selling at Takeda=Smoke and Mirrors

Quote

Anonymous

Guest
When your products are me-too's with NO advantages over the generic competitors,it is very hard to get motivated,especially when you see the physicians roll their eyes as you try anything to sell these dogs.And please,please stop making us push that lame Plavix study as the ACG says there are no issues with any PPI's.Where have the ethics gone in this company?Down the toilet with everthing else that was good about Takeda.
 




















Anonymous said:
When your products are me-too's with NO advantages over the generic competitors,it is very hard to get motivated,especially when you see the physicians roll their eyes as you try anything to sell these dogs.And please,please stop making us push that lame Plavix study as the ACG says there are no issues with any PPI's.Where have the ethics gone in this company?Down the toilet with everthing else that was good about Takeda.
Click to expand...

Agreed!One of my Dexi speakers continued to write more Nexium than Dexi through the whole Plavix situation.
 




Anonymous said:
Agreed!One of my Dexi speakers continued to write more Nexium than Dexi through the whole Plavix situation.
Click to expand...

Look a Susan Lucak in NY. She's writing Linzess like its water. Yet, Takeda continues to tout her as our national thought leader with her face on the cover of promotional materials etc. Why even bother with a speaker bureau and marketing?
 








Anonymous said:
Look a Susan Lucak in NY. She's writing Linzess like its water. Yet, Takeda continues to tout her as our national thought leader with her face on the cover of promotional materials etc. Why even bother with a speaker bureau and marketing?
Click to expand...

How is that so? According to my amitiza pod partner, NO ONE is writing Linzmess!
 




Anonymous said:
How is that so? According to my amitiza pod partner, NO ONE is writing Linzmess!
Click to expand...

So your pod partner is drunk koolaid and offered you a sip. The Amitiza HD report has a tab that lists all the prescribers of Linzess in the nation. We work with nothing. No money to launch the OIC indication, no activity by specialty reps and no response from marketing. Our leadership in this market is rapidly slipping away
 




Anonymous said:
How is that so? According to my amitiza pod partner, NO ONE is writing Linzmess!
Click to expand...

More on Ironwood Pharmaceuticals' (IRWD) Q2: Linzess sales come in at $28.8M, up more than five...
Tuesday, July 23, 7:49 AM ET
More on Ironwood Pharmaceuticals' (IRWD) Q2: Linzess sales come in at $28.8M, up more than five fold from Q1; there were ~125K prescriptions filled during the period. The company, along with Forest Labs, is exploring "additional development opportunities to strengthen the clinical profile of Linzess." The two companies plan to report data from a Phase IIIb trial evaluating the drug on CIC patients' abdominal symptoms in Q3 and expect "to initiate U.S. clinical trials" for other indications in Q1 2014. IRWD reaffirms FY13 total sales and marketing expenses of $250-300M for the drug. Shares +10.65% premarket. (PR)

The jokes on you buddy
 




Anonymous said:
More on Ironwood Pharmaceuticals' (IRWD) Q2: Linzess sales come in at $28.8M, up more than five...
Tuesday, July 23, 7:49 AM ET
More on Ironwood Pharmaceuticals' (IRWD) Q2: Linzess sales come in at $28.8M, up more than five fold from Q1; there were ~125K prescriptions filled during the period. The company, along with Forest Labs, is exploring "additional development opportunities to strengthen the clinical profile of Linzess." The two companies plan to report data from a Phase IIIb trial evaluating the drug on CIC patients' abdominal symptoms in Q3 and expect "to initiate U.S. clinical trials" for other indications in Q1 2014. IRWD reaffirms FY13 total sales and marketing expenses of $250-300M for the drug. Shares +10.65% premarket. (PR)

The jokes on you buddy
Click to expand...

Ben Dover
 




Anonymous said:
More on Ironwood Pharmaceuticals' (IRWD) Q2: Linzess sales come in at $28.8M, up more than five...
Tuesday, July 23, 7:49 AM ET
More on Ironwood Pharmaceuticals' (IRWD) Q2: Linzess sales come in at $28.8M, up more than five fold from Q1; there were ~125K prescriptions filled during the period. The company, along with Forest Labs, is exploring "additional development opportunities to strengthen the clinical profile of Linzess." The two companies plan to report data from a Phase IIIb trial evaluating the drug on CIC patients' abdominal symptoms in Q3 and expect "to initiate U.S. clinical trials" for other indications in Q1 2014. IRWD reaffirms FY13 total sales and marketing expenses of $250-300M for the drug. Shares +10.65% premarket. (PR)

The jokes on you buddy
Click to expand...

Markets closed, share are flat. Nice try, Irondick. You have 19 scripts of Linzmess in my territory since launch. Look at the financials. If your company actually made any money, you wouldn't be driving that smelly rental car I see you in.
 








Anonymous said:
Markets closed, share are flat. Nice try, Irondick. You have 19 scripts of Linzmess in my territory since launch. Look at the financials. If your company actually made any money, you wouldn't be driving that smelly rental car I see you in.
Click to expand...
I think thou doth protest too much.

Tuesday, July 23, 7:49 AM ET
More on Ironwood Pharmaceuticals' (IRWD) Q2: Linzess sales come in at $28.8M, up more than five fold from Q1; there were ~125K prescriptions filled during the period.

http://seekingalpha.com/currents/post/1152992?source=email_rt_mc_readmore
 








Top Bottom
Back
Quote